COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
18 hedge funds and large institutions have $969K invested in COSCIENS Biopharma Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 7 closing their positions.
103% more capital invested
Capital invested by funds: $478K → $969K (+$491K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
38% more funds holding
Funds holding: 13 → 18 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$664K |
| 2 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$168K |
| 3 |
Two Sigma Investments
New York
|
+$84K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$75.6K |
| 5 |
Morgan Stanley
New York
|
+$67.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Aperio Group
Sausalito,
California
|
-$82K |
| 2 |
Jane Street
New York
|
-$52K |
| 3 |
JP Morgan Chase
New York
|
-$43K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$25.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$25K |
CSCI Hedge Fund Activity: Q4 2014 in Review
18 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2014, worth a combined $969K — up 103% from $478K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CSCI positions and 7 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $664K. The largest seller was Aperio Group, exiting entirely with an estimated $82K sold.
- 18 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2014, up from 13 in Q3 2014.
- Funds reported $969K of COSCIENS Biopharma Inc. Common Stock stock for Q4 2014, up 103% quarter-over-quarter.
- 12 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2014 and 7 closed out, a net change of +5 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2014 was Hudson Bay Capital Management, an estimated $664K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2014 was Aperio Group, an estimated $82K sold.
Based on aggregated 13F filings for Q4 2014.